Xellia Pharmaceuticals Opens North American Commercial Office in Chicago Ahead of Launching Value-Added Anti-Infective Injectable Drug Products

COPENHAGEN, Denmark--(BUSINESS WIRE)-- Xellia Pharmaceuticals (Xellia or the Company), a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections, today announced that it has opened a new office in Buffalo Grove, near Chicago, Illinois to accommodate the Company’s expanding North American commercial organization.

Craig Boyd, who was appointed as President of Xellia’s North American operations in April 2018, will lead the commercial team to spearhead the launch of the Company’s value-added anti-infective products into the hospital markets. In addition, the team will establish partnerships for Xellia’s sterile injectable product manufacturing site in Cleveland, Ohio that is being developed to increase the supply of these products in the US.

The official office opening that took place yesterday was celebrated with a ribbon cutting ceremony. The event was attended by Xellia’s leadership team, members of the Board and the newly appointed commercial team of experienced pharmaceutical executives. This team includes a dedicated sales force which will cover North America.

On the opening of the office and welcoming the new commercial team, Carl-Åke Carlsson, Xellia’s CEO said:
“Building on our long experience as a world-leading trusted supplier of important anti-infective drugs, the opening of the Office is a significant milestone in our ambitious plans to further evolve and grow our business. As well as being pivotal in the launch of our new pipeline into the US hospital markets, our newly formed commercial organization will play an important role in marketing our increased manufacturing and sterile injectable capabilities in Cleveland.”

Craig Boyd, President of Xellia US, said:
“We are expanding rapidly and our dedicated sales force will launch our new products in the US hospital markets. With a wealth of local expertise, we are perfectly situated to expand our workforce with talented staff who understand injectable products and the needs of our customers.”

Since 2014, Xellia has been developing a pipeline of value-added anti-infective drugs centred on formulation improvements for marketed drugs from its core portfolio. These products are intended to enhance patient care by providing convenience and ease of use for healthcare professionals.

Earlier this year the Company submitted a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for its lead value-added product, Premixed Vancomycin Ready-to-Use (RTU) Bag. This product has also been granted Qualified Infectious Disease Product (QIDP) designation by the FDA.

- Ends -

Images of the Chicago office opening event are available upon request from xellia@instinctif.com.

About Xellia Pharmaceuticals

Xellia Pharmaceuticals (“Xellia”) is a specialty pharmaceutical company developing, manufacturing and commercializing anti-infective treatments against serious and often life-threatening bacterial and fungal infections.

With over 100 years of experience, Xellia is a world-leading trusted supplier of several important established anti-infective drugs, comprising active pharmaceutical ingredients as well as injectable products. Continuing the Company’s evolution, Xellia is generating an innovative pipeline of value-added anti-infective medicines intended to enhance patient care, providing convenience and ease-of-use for healthcare professionals.

Headquartered in Copenhagen, Denmark, Xellia has a global footprint with R&D, manufacturing and commercial operations across Europe, Asia and North America and is investing significantly to expand its sales and manufacturing capabilities within the United States. Xellia is wholly owned by Novo Holdings A/S and employs a dedicated team of over 1,500 people.

Further information about Xellia can be found at: www.xellia.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180918005572/en/